Appendix

Table 1: Unit Costs for Healthcare Utilization

Table 2: Treatment Characteristics at level2

Algorithm to determine the start and end dates of medication use

To accurately reflect the study medication use at level2 of the trial, the start date was either the date of beginning of level2 or the recorded medication start date, whichever was later. In case of missing end dates at any assessment, the medication was assumed to be continued until the start date of the subsequent record of the same medication (or same medication type in case of concomitant medications). If the end date was missing at the last observation for a patient then the study medication was assumed to be continued up until the end of the level.

Table 3: Unit Costs for Healthcare Utilization (US dollars 2014): Appendix

Costs/unit	Mean	SD	Reference
Depression Medications ($/ gm)			
Bupropion	.04	.006	Red Book, Fundamental Reference
Sertraline	.09	.05	Red Book, Fundamental Reference
Venlafaxine	.09	.04	Red Book, Fundamental Reference
Citalopram	.24	.15	Red Book, Fundamental Reference
Nortryptline	1.17	1.07	Red Book, Fundamental Reference
Concomitant Medications ($/day)			
Trazodone	2.13	1.82	Red Book, Fundamental Reference
Sedatives	5.92	6.39	Red Book, Fundamental Reference
Anxiolytics	10.11	8.24	Red Book, Fundamental Reference
GI Medications	1.91	3.23	Red Book, Fundamental Reference
Erectile Dysfunction Medications	21.46	13.14	Red Book, Fundamental Reference
Healthcare Facility			
Outpatient Visit ($/visit)	66.59	44.53	Physician Fee Schedule
Emergency Room ($/visit)	83.32	62.17	Physician Fee Schedule
Hospitalization ($/day)	2446	22.52	HCUP

Table 4: Treatment Characteristics at Level2 Appendix

	BUP (N=239)		SER (N=238)		VEN (N=250)		P-value
	N	%	N	%	N	%	
Time in level2 (weeks), Mean (SD)	8.3 (5.01)	5	9.1	5	9.3	5	.058
Action at level2 End							.092
Follow-up (n=257)	69	29	87	37	101	40	
Terminate/Dropouts (n=243)	87	36	75	32	81	32	
Enrolled in L3 (n =227)	83	35	76	32	68	27	

*Kruskal-wallis for continuous variable and chi-square for categorical variable

Figure 1: Scatter plot reflecting uncertainty in costs and effectiveness

Cost Effectiveness Plane

Difference in QIDS-SR Scores

Difference in Costs ($)

■ Incremental Difference between Bupripion and Sertraline
▲ Incremental Difference between Sertraline and Venlafaxine
◆ Incremental Difference between Bupripion and Venlafaxine